Abstract Estrogen receptor-a (ER) targeted therapies are routinely used to treat breast cancer. However, patient responses are limited by resistance to endocrine therapy. Breast cancer cells resistant to the pure steroidal ER antagonist fulvestrant (fulv) demonstrate increased activation of epidermal growth factor receptor (EGFR) family members and downstream ERK signaling. In this study, we investigated the effects of fulv on EGFR signaling and ligand regulation in several breast cancer cell lines. EGFR/ HER2/HER3 phosphorylation and ERK1,2 activation were seen after 24-48 h after fulvestrant treatment in ER-positive breast cancer cell lines. 4-Hydroxy-tamoxifen and estradiol did not cause EGFR activation. Fulvestrant did not affect EGFR expression. Cycloheximide abolished the ability of fulv to activate EGFR suggesting the autocrine production of EGFR ligands might be responsible for fulvestrant induced EGFR signaling. qRT-PCR results showed fulv differentially regulated EGFR ligands; HB-EGF mRNA was increased, while amphiregulin and epiregulin mRNAs were decreased. Fulvestrant induced EGFR activation and upregulation of EGFR ligands were ER dependent since fulv treatment in C4-12, an ER-negative cell line derivative of MCF-7 cells, did not result in EGFR activation or change in ligand mRNA levels. ER downregulation by siRNA induced similar EGFR activation and regulation of EGFR ligands as fulvestrant. Neutralizing HB-EGF antibody blocked fulv-induced EGFR activation. Combination of fulv and EGFR family tyrosine kinase inhibitors (erlotinib and lapatinib) significantly decreased EGFR signaling and cell survival. In conclusion, fulvestrant-activated EGFR family members accompanied by ER dependent upregulation of HB-EGF within 48 h. EGF receptor or ligand inhibition might enhance or prolong the therapeutic effects of targeting ER by fulvestrant in breast cancer.
Introduction
The majority of breast cancers express estrogen receptor-a (ER), and endocrine therapy is effective in a subset of these tumors. Currently, several ER-targeting drugs are available [1, 2] . The two major classes are selective ER modulators (SERM) and aromatase inhibitors. Fulvestrant is a pure steroidal SERM that downregulates ER expression in model systems [3, 4] . Compared to tamoxifen, fulvestrant has no agonist activity. Despite the ability of fulvestrant to more completely inhibit ER, it is not clinically superior to tamoxifen even as first line therapy for metastatic disease [5] . While dosing of fulvestrant is important in optimizing response [6] , de novo or acquired endocrine therapy resistance limits prolonged disease stabilization. Understanding how SERMs affect breast cancer cell biology could provide additional insight into improving initial therapeutic benefit and delaying or avoiding resistance.
In this study, we focused on the drug fulvestrant. Compared to tamoxifen, fulvestrant binding to ER results in inhibition of receptor dimerization, rapid and strong degradation of ER, and disruption of its function [7, 8] . The potential mechanisms of fulvestrant resistance are not fully understood, but increased epidermal growth factor receptor (EGFR) signaling and/or increased EGFR family member protein expression have been implicated in resistance to ER therapies [9] [10] [11] . However, the addition of EGFR inhibitors to endocrine therapies have not shown increased clinical benefit compared to the endocrine therapy alone [11] [12] [13] . Further understanding of the crosstalk between these two systems might help define improved therapeutic strategies.
Epidermal growth factor receptor family comprises four closely related receptors: EGFR (HER1), HER2, HER3, and HER4. All HERs are tyrosine kinase receptors except for HER3. Binding of ligands to extracellular domain of EGFR, HER3, and HER4 induce receptor dimerization leading to the activation of downstream MAPK, PI3K, STAT, and Src kinase pathways [14] . Currently, 10 EGF ligands have been reported [15] . Epidermal growth factor (EGF), transforming growth factor-a (TGF-a), and amphiregulin (AREG) bind to EGFR; heparin-binding EGF-like growth factor (HB-EGF), beta-cellulin (BTC), and epiregulin (EPR) bind to both EGFR and HER4; neuregulin-1 (NRG-1) and NRG-2 bind both HER3 and HER4; and NRG-3 and NRG-4 bind to HER4. These ligands can be membrane-anchored precursor protein or soluble form ligands cleaved from the membrane by metalloproteinases. Therefore, depending on the cellular environment, these ligands induce juxtacrine, autocrine, paracrine, and/or endocrine signaling [16] . EGF ligands and their receptors are involved in many aspects of cancer cell biology and have served as targets for several successful cancer therapies.
Several groups [17] [18] [19] [20] [21] have developed fulvestrant resistant breast cancer cell lines and reported increased EGFR/HER2 activation with subsequent downstream activation of ERK1,2 signaling. Specific EGFR tyrosine kinase inhibitors, gefitinib and pan-HER inhibitor CI-1033 are effective in inhibiting fulvestrant resistant MCF-7 breast cancer cell growth [9, 21] . However, it takes several months to develop resistance to fulvestrant. During this period, cells may undergo many selective changes that were not present de novo.
The purpose of this study was to investigate the effects of fulvestrant on EGFR signaling and ligand regulation in wild-type, hormone sensitive, ER-positive breast cancer cells for a better understanding of the potential mechanisms of fulvestrant resistance. We have found that fulvestrant, but not tamoxifen or estradiol (E2), upregulated HB-EGF to activate EGFR signaling. Increased HB-EGF expression was mediated by ER expression suggesting that a specific role for fulvestrant in regulating ER-mediated transcription of EGF family ligands.
Materials and methods

Cells and reagents
Human breast cancer cell lines MCF-7L was from Dr. C. Kent Osborne (Baylor College of Medicine, Houston, Texas), MCF-7 ATCC and T47D were obtained from ATCC and are routinely cultured in our lab [22, 23] . C4-12 [24] , an ER-negative cell line derived from MCF-7L was kindly provided by Dr. Adrian V. Lee (Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, Magee Women Research Institute, Pittsburgh, Pennsylvania, USA). C4-12 cells were maintained in phenol red-free aMEM and supplemented with 5 % charcoal/dextran-treated FBS.
Fulvestrant (ICI 182,780) was purchased from Tocris Bioscience (Bristol, UK). The working concentration for all the experiments was 100 nM. E2, 4-hydroxy-tamoxifen (4HT), cycloheximide (CHX), and anti-actin antibody were purchased from Sigma (ST. Louis, MO). Experimental concentrations used were 10 nM for E2 and 100 nM for 4HT. Erlotinib and lapatinib were purchased from BioVision Research Products (Mountain View, CA). Neutralizing HB-EGF antibody was purchased from R&D Systems, Inc. (Minneapolis, MN). Anti-phospho-Tyr antibody (PY20) was a product of BD Biosciences (San Jose, CA). pEGFR-Y1068, EGFR, pHER2-Y1228, HER2, pHER-3-Y1289, HER3, pERa (ser167), pERa (ser 118), ERa, PARP, pAKT, AKT, pERK1,2, and ERK1,2 antibodies were from Cell Signaling Technology, Inc. (Danvers, MA). Human ESR1 siRNA was from Dharmacon, (Lafayette, CO) and control siRNA was from Santa Cruz, CA.
Cell lysate preparation
Cells were serum-starved 24 h before any treatment. At the end of the treatment, cells were washed once in ice cold phosphate buffered saline (PBS, Biofluids, Rockville, MD). Cells were then lysed with 200 ll per 6 cm plate with TNESV buffer (50 mM-Tris-pH 7.4, 1 % NP-40, 2 mM EDTA, 100 mM NaCl, 10 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride, 20 lg/ml leupeptin, and 20 lg/ml aprotinin). Protein concentration of the cleared lysates was determined by the copper-bicinchoninic acid method with a Pierce Laboratory kit (Rockford, IL).
Immunoblotting
After SDS-PAGE proteins were transferred overnight to nitrocellulose membranes (Bio Rad, Hercules, CA). All blotting steps were carried out at room temperature with gentle rocking. The membranes were blocked in 5 % nonfat dry milk in Tris-buffered saline-Tween 20 (TBST: 0.15 M CaCl 2 , 0.01 M Tris-HCl-pH 7.4, 0.05 % Tween 20). For antiphosphotyrosine blotting with PY-20, membranes were washed five times over 30 min with TBST after blocking, incubated with a 1:2,000 dilution of PY-20 in TBST for 1 h, washed, and binding was detected by chemiluminescence as described below. The other immunoblots were performed with overnight incubation at 4°C in the primary antibody. Blots were then washed and incubated with a 1:2,000 dilution of HRP linked antirabbit or mouse secondary antibody in blocking buffer for 1 h, followed by further washing. Enhanced chemiluminescence was performed according to manufacturer's instructions (Pierce, Rockford, IL).
Immunoprecipitation 500 lg protein cell lysate was used for immunoprecipitation with 1:100 EGFR, HER2, or HER3 antibodies in 0.5 ml TNSEV buffer for 2 h at 4°C. Then, 25 ml protein-A agarose beads was added with gentle rock at 4°C overnight. Beads were washed five times and pull down proteins were used for immunoblotting with PY20 or phospho-specific receptor antibodies.
Live cell quantification
Cells in serum-containing medium were seeded as triplicate sets into 24-well plates with 100,000 cells per well. Cells were switched to serum-free medium for 24 h and then treated with or without fulvestrant in the presence or absence of erlotinib (10 lM) or lapatinib (1 lM). Live cell number was quantified at day 3 after treatment by the MTT assay. In brief, 60 ll of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide solution in PBS was added to each well. After incubation for 3 h at 37°C, wells were aspirated, and formazan crystals were lysed with 500 ll of solubilization solution (95 % DMSO ? 5 % Improved Minimal Essential Medium). Absorbance was measured with a plate reader at 570 nm by using 670 nm differential filter.
Reverse transcription-quantitative real-time polymerase chain reaction (qRT-PCR) MCF-7L, T47D, MCF-7 ATCC, and C4-12 cells were treated with E2, 4HT, and fulvestrant for 1, 4, 24, and 48 h. mRNA was purified with TriPure Isolation Reagent according to the manufacturer's instructions (Roche Diagnostics, Indianapolis, IN). A total of 2 lg of RNA was reverse transcribed using the transcriptor first strand cDNA synthesis kit (Roche), and quantitative PCR was performed using the FastStart universal SYBR Green kit according to the manufacturer's recommended protocol (Roche). All primers were synthesized at BioMedical Genomics Center at the University of Minnesota.
Statistical analysis
Statistical significance between two groups was tested using Student's t test. Error bars represent SD and asterisks denote statistical significance (p \ 0.05).
Results
Fulvestrant induced EGFR family member activation and downstream MAPK signaling
In order to determine if EGFR family members were activated upon fulvestrant treatment in naive breast cancer cells, we first treated MCF-7L cells with 100 nM fulvestrant. To identify specific EGFR family members, we immunoprecipitated (i.p.) cell lysates with specific antibodies followed by antiphosphotyrosine immunoblotting. Figure 1a shows that short-term fulvestrant treatment (10 min) did not induce EGFR receptor activation, while prolonged exposure (24-48 h) resulted in EGFR, HER2, and HER3 phosphorylation. Antiphosphotyrosine total cell lysate immunoblotting was consistent with the results from immunoprecipitation of specific EGFR family members ( Fig. 1c and data not shown). Bands detected by antiphosphotyrosine blotting were consistent with the molecular weight of the EGFR family members. ER phosphorylation was decreased when ER was downregulated by fulvestrant (Fig. 1b) . Under prolonged serum-free conditions, ERK1,2 activation was detected likely due to stress induced under these culture conditions. However, fulvestrant further induced a higher level of activation (Fig. 1b) . We did not see significant changes in pAKT level suggesting that PI3K signaling pathway was not induced by fulvestrant (data not shown). As shown in Fig. 1c , EGFR and downstream ERK1,2 signaling were blocked by the EGFR family member tyrosine kinase inhibitors, erlotinib and lapatinib. Since EGFR and downstream MAPK or PI3K signaling pathway were also reported to play roles in tamoxifen resistant breast cancer cells [25] , we then treated MCF-7L and T47D cells with 4-hyrdoxy tamoxifen (4HT) and E2 to determine if this fulvestrant activation of EGFR family members was specific. As shown in Fig. 1d , only fulvestrant treatment induced activation of EGFR phosphorylation. It is notable that E2 was unable to mimic the effects of fulvestrant suggesting that ligand binding to the ER alone was not sufficient to initiate EGFR family member signaling.
Fulvestrant induced upregulation of mRNA of EGFR ligand HB-EGF
Fulvestrant induced EGFR activation only occurred after 24 h suggesting that juxtacrine or autocrine expression of EGFR ligands might be induced by fulvestrant. To determine if mRNA translation was needed, we treated MCF-7L cells with CHX, an inhibitor of translation, and fulvestrant for 48 h. As it is shown in Fig. 2a , CHX abolished the ability of fulvestrant to activate EGFR suggesting that autocrine production of EGFR ligands might be induced by fulvestrant. PARP cleavage was not seen after CHX, suggesting that apoptosis was not induced (data not shown).
To detect specific EGFR ligands, we used qRT-PCR at 1, 4, 24, and 48 h after fulvestrant, 4HT, and E2 treatment. As shown in Fig. 2b , both E2 and fulvestrant increased TGFa mRNA levels starting at 24 h and were sustained through 48 h. HB-EGF mRNA level was significantly increased only after 48 h of fulvestrant treatment which correlated with the time course of EGFR activation. 4-HT did not affect mRNA levels of these ligands. In contrast, AREG and EPR mRNA levels were substantially reduced 48 h after fulvestrant treatment. A similar trend was seen for AREG and EPR mRNA levels in 4HT treated cells but to a much lesser extent. These results demonstrated that ER ligands specifically and differentially regulated EGFR ligand gene expression with fulvestrant causing upregulation of HB-EGFR and downregulation of AREG and EPR messages. The similar observation was seen in MCF-7 ATCC and T47D cells (Fig. 2c) . We also examined the cells for expression of EGF, NRG-1, BTC, and epigen and saw no expression or regulation (data not shown). 
Fulvestrant induced EGFR family member activation required ER
To further determine if the fulvestrant effects were ER dependent, we used an ER-negative breast cancer cell line (C4-12) derived from MCF-7L cells [24] . MCF-7L and C4-12 cells were treated with and without fulvestrant for 48 h. As shown in Fig. 3a , fulvestrant did not induce EGFR phosphorylation in C4-12 cells. Next, we did qRT-PCR after 48 h treatment of fulvestrant and 4HT. Again, HB-EGF and TGFa mRNA levels remained unchanged by both fulvestrant and 4HT (Fig. 3b) . These results suggested that ER is necessary and required for fulvestrant induced EGFR activation.
Fulvestrant induced EGFR phosphorylation required HB-EGF function
To determine a functional role for HB-EGF, MCF-7L cells were treated with 1.0-5.0 lg/ml neutralizing HB-EGF antibody together with fulvestrant for 24 h. As shown in Fig. 4a , EGFR phosphorylation was partially inhibited by neutralizing HB-EGF antibody. We also used HB-EGF siRNA to downregulate expression. Figure 4b shows that HB-EGF downregulation inhibited the ability to activate EGFR, while TGFa siRNA did not. In addition, HB-EGF siRNA alone and in combination with fulvestrant further inhibited monolayer growth, while TGFa siRNA did not (data not shown). These findings were consistent with the idea that upregulation of HB-EGF mRNA by fulvestrant resulted in stimulation of EGFR family members and decreased response to fulvestrant.
Combination treatment of fulvestrant with EGFR inhibitors, erlotinib or lapatinib, significantly decreased cell growth
To further explore the biological role of fulvestrant induced EGFR activation in MCF-7L cell biology, we examined the effects of EGFR TKIs on cell survival. Figure 5 shows that in serum-free conditions, fulvestrant treatment reduced MCF-7 cell numbers compared to control. Erlotinib (10 lM) or lapatinib (1 lM) with fulvestrant further reduced cell numbers beyond fulvestrant alone. Therefore, while fulvestrant downregulated ER and inhibited cell growth and survival, suppression of EGFR family signaling further reduced cell numbers. Thus, EGFR family signaling might play a role in the development of fulvestrant resistance.
ER downregulation by siRNA also induced EGFR activation and ligand expression in MCF-7L cells Fulvestrant downregulates ER protein levels. Since ER can function as a transcriptional activator or repressor, we decreased ER expression using ESR1 siRNA to mimic fulvestrant's effects on ER levels. As shown in Fig. 6a , similar to fulvestrant treatment, cells exposed to an ESR1 siRNA for 48 h resulted in increased HB-EGF mRNA and decreased AREG mRNA levels in MCF-7L cells when compared to control siRNAs. EGFR phosphorylation was increased in ESR1 siRNA alone and in combination with fulvestrant (Fig. 6b) . As shown in Fig. 6c , fulvestrant treatment upregulated HB-EGF and downregulated AREG in both control siRNA transfected (Ctrl) cells and ESR1 siRNA transfected (ESR1) MCF-7L. Increased HB-EGF mRNA levels in ESR1 transfected MCF-7L cell after fulvestrant treatment suggest that downregulation of ER by siRNA and fulvestrant treatment both had effect on EGFR ligands upregulation.
Discussion
It is well documented that the existence of crosstalk between ER and EGFR in a bidirectional way in breast cancer cells via ER genomic and nongenomic functions in an E2 dependent or independent manner [26, 27] . Clinical and experimental [8, 11] observations suggest that breast tumors exhibit an inverse relationship between ER and EGFR expression, but detailed studies are lacking on tumor tissue from before treatment and after resistance has developed. Fulvestrant, as a pure ER antagonist, not only blocks ER function, but also rapidly degrades ER as a selective estrogen receptor degrader (SERD). Since it is well known that E2 regulates EGFR family ligands, we evaluated the effects of fulvestrant on this growth factor system. Prolonged exposure to fulvestrant, but not E2 or tamoxifen, resulted in activation of all EGFR family members. Total EGFR and TGFa levels remained unchanged consistent with previously published data [28, 29] . It has been reported that E2 and SERMs including tamoxifen, raloxifene, and fulvestrant differentially regulate gene expression in breast cancer and endometrial cancer cells [30] [31] [32] [33] . Among those genes are EGFR ligands AREG and TGFa. We have shown that fulvestrant induced activation of EGFR system (Fig. 1) and conditioned media collected from fulvestrant-treated cells activated EGFR in nonfulvestrant-treated breast cancer cells (data not shown). These data suggested that EGFR ligands were upregulated by fulvestrant, and we used qRT-PCR technology to show HB-EGF and AREG were specifically regulated by fulvestrant, with an increase of HB-EGF and decrease of AREG mRNA levels in ER-positive breast cancer cells.
This effect required ER expression as downregulation of ER by siRNA blunted the fulvestrant effect. Hutcheson et al. [34] reported recently that in ER-positive breast cancer cells, fulvestrant treatment sensitized cells to heregulin b1. However, we did not observe NRG1 gene expression which may due to the gene silencing by methylation commonly observed in breast cancer cells [35] . Our data do not support a role for NRG1 in fulvestrant induced EGFR activation. Our qRT-PCR data suggested that differential regulation of EGFR ligands HB-EGF and AREG by fulvestrant treatment contributed to EGFR family member activation and was dependent on ER expression. HB-EGF neutralizing antibody partially blocked EGFR phosphorylation (Fig. 4) further supports this notion. Results from monolayer cell growth analysis ( mainly support cell survival after loss of ER. It is notable that E2 does not result in EGFR activation further highlighting the importance of ER downregulation in activating this signaling pathway. The time course of ER loss may also be important. The C4-12 cells, which were derived from MCF-7 and have lost ER, do not have upregulation of this signaling pathway. These cells were created by clonal selection under estrogen deprived conditions over many months [10] . Thus, acute downregulation of ER by a drug has different effects that loss of ER over time estrogen deprivation. Preclinical data implicate EGFR system signaling as a mechanism of endocrine resistance. However, clinical trials combining fulvestrant or aromatase inhibitors with EGFR tyrosine kinase inhibitor, gefitinib, in phase II clinical trials showed disappointing results [11, 13] . It is notable that the dose of fulvestrant used in these early trials was low compared to the recently approved dosing and schedule [6] . In addition, a lack of selection of patients with activated EGFR signaling could contribute to these negative results for the combination trials. It is likely that only a minority of patients demonstrate ER expression and EGFR activation. Our results showed that decreased levels of ER protein resulted in EGFR activation; EGFR inhibitors, erlotinib and lapatinib, effectively inhibited cell growth beyond that achieved by fulvestrant alone. This is consistent with the report that low ER levels, but not EGFR, correlated with benefit from gefitinib [12] . Therefore, sequential or concurrent treatment of an EGFR inhibitor with fulvestrant might further enhance clinical benefit in tumors with activated EGFR signaling.
All the EGFR family members are transcriptionally repressed by estrogen [36] and in MCF-7 breast cancer cells, stably overexpressed EGFR or constitutively active HER2, Raf, or MAP/extracellular signal regulated kinase, resulted in cell lines exhibiting hyperactivation of MAPK, estrogen-independent growth, and the reversible downregulation of ERa expression [37] . As mentioned before, one of the major actions for fulvestrant is rapidly downregulating ER. Stope et al. [38] have reported that ERa attenuates TGFb signaling in breast cancer cells independent from agonistic and antagonistic ligands. E-cadherin transcription has been reported and activated by unliganded ERa and suppressed by estrogen-activated ERa [39] . The transfection of ERa cDNA into MDA-MB-231 cells also resulted in downregulation of Toll-like receptor-9 (TLR9) expression [40] . Furthermore, Luqmani et al. [41] used siRNA to target ERa in MCF-7 human breast cancer cells and observed an array of gene expression changes. Our data support the idea that loss of unliganded ER results in changes in gene expression as ER siRNA increased EGFR phosphorylation via changes in HB-EGF without affecting total EGFR levels. These data suggested that while fulvestrant induced potent growth-inhibitory effect in ER-positive breast cancer cells, it also simultaneously induced EGFR pathway through downregulation of ER and upregulation of EGFR ligands that override the initial response to fulvestrant and might ultimately result in a resistance phenotype.
In conclusion, fulvestrant as an endocrine therapy for ER-positive breast cancer effectively inhibits ER dependent cell growth and cell survival with important clinical activity, but also results in enhanced EGFR signaling and EGFR ligand expression in an ER dependent manner. As Sonne-Hansen et al. [21] reported, breast cancer cells can switch between ERa and EGFR signaling. SERMs affect ER-mediated gene transcription. While growth regulatory genes may be suppressed, other genes are de-repressed and with ;100 nM fulvestrant for 48 h. Cell lysates were used for western blotting for PY20 (receptor activation) and total EGFR and ERa. Actin blot was used as loading control. c All cells were treated with ;100 nM of fulvestrant for 48 h. Then qRT-PCR was performed by using HB-EGF and AREG specific primers. % change of mRNA levels was shown in the figure by using Ctrl siRNA transfected cells (SFM) as control their expressions are induced. Some of these genes may contribute to the invasive cell phenotype as reported by Borley et al. [42] . Therefore, combined treatment against both signaling pathways could enhance the benefit of fulvestrant. Our experiments suggest that blockade of EGFR family members might affect the primary or secondary resistance which could be explored directly in patients receiving fulvestrant.
